Maxim Group analyst Jason McCarthy maintained a Buy rating on VolitionRX (NYSE: VNRX) today and set a price target of $6. The company’s shares opened today at $2.21.
McCarthy wrote:
“VolitionRx announced additional agreements to conduct colorectal cancer (CRC) screening studies in the Asian-Pacific region. This is a strategic positive for the company, in our view, as this region is one of the target markets for Nu.Q.”
According to TipRanks.com, McCarthy is a 4-star analyst with an average return of 10.7% and a 44.5% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, SELLAS Life Sciences Group Inc, and ContraVir Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for VolitionRX with a $6.50 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $4 and a one-year low of $1.85. Currently, VolitionRX has an average volume of 60.85K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
VolitionRX Ltd. engages in the development of blood-based cancer tests. Its product Nu.Q is a colorectal cancer screening triage test. The company was founded on August 5, 2010 and is headquartered in Singapore.
